Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: A multicenter phase II pilot study

Claudio Dazzi, Anna Cariello, Giovanni Rosti, Amelia Tienghi, Annamaria Mouno, Roberto Sabbatini, Michele Aieta, Gian Luca Frassineti, Bernadette Vertogen, Petros Giovanis, Maurizio Marangolo

Research output: Contribution to journalArticle

Abstract

Background and Objectives. With the introduction of combined modality therapy, approximately 30% of patients wth inflammatory breast cancer (IBC) are alive and free of disease at 5 years, but the lack of control of systemic disease continues to be the main reason for treatment failure. The importance of the response to primary chemotherapy and, in particular, complete tumor regression after primary chemotherapy have previously been described to be among the most reliable prognostic factors along with the dose intensity of doxorubicin. Design and Methods. To evaluate pathologic response rate and toxicity of neoadjuvant high dose chemotherapy (HDCT) with autologous peripheral blood progenitor cell (PBPC) support in patients affected by IBC, 21 patients were enrolled in a study in which it was planned that they would receive 4 courses of epirubicin 150 mg/m2 plus granulocyte colony-stimulating factor (G-CSF) as induction and mobilizing chemotherapy. Patients with non-progressive disease were intended to receive 2 consecutive courses of a combination of high doses of mitoxantrone 40 mg/m2, thiotepa 500 mg/m2 and cyclophosphamide 200 mg/kg as a conditioning regimen. Results. PBPC collection was successful in 20/21 patients. Twelve patients received a single course of HDCT, whereas 7/20 patients underwent a double procedure. At a median follow up of 48 months, 20/21 patients were evaluable for toxicity and 19/21 for response. At surgery 4/19 patients (21%) had no evidence of viable tumor cells in the breast and in axillary nodes, while 4 (21%) and 11 patients (58%) had microscopic and macroscopic disease, respectively. Eight patients have relapsed (35%) so far at a median of 16 months (9-54 ) from diagnosis. Eleven patients remain alive without evidence of disease. Five out of 20 patients experienced severe cardiotoxicity with congestive heart failure (CHF) which was responsible for the only treatment-related death. Interpretation and Conclusions. This neoadjuvant HDCT regimen seems to be very effective in terms of objective responses, but we observed a high rate of cardiotoxicity and only a few patients were able to receive the two planned courses of high dose chemotherapy.

Original languageEnglish
Pages (from-to)523-529
Number of pages7
JournalHaematologica
Volume86
Issue number5
Publication statusPublished - May 2001

Keywords

  • Cardiotoxicity
  • High dose chemotherapy
  • Inflammatory breast cancer

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: A multicenter phase II pilot study'. Together they form a unique fingerprint.

  • Cite this

    Dazzi, C., Cariello, A., Rosti, G., Tienghi, A., Mouno, A., Sabbatini, R., Aieta, M., Luca Frassineti, G., Vertogen, B., Giovanis, P., & Marangolo, M. (2001). Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: A multicenter phase II pilot study. Haematologica, 86(5), 523-529.